Roche’s new round of lung cancer data keeps spotlight on immunotherapies – FierceBiotech

by lowes1 on October 3, 2013

Roche's new round of lung cancer data keeps spotlight on immunotherapies
FierceBiotech
Roche's ($RHHBY) too-hot-to-handle PD-L1 drug MPDL3280A jumped back in the spotlight over the weekend. Researchers posted early-stage data demonstrating that the treatment–which takes the blinders off the immune system to spur an attack on 

and more »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: